September 2012, 10:117,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 22 Sep 2012
Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey
The prevalence of gout is increasing, and most research on the associated burden has focused on serum urate (sUA) levels. The present study quantifies the impact of the presence of tophi and frequency of acute gout attacks on health-related quality of life (HRQOL), productivity, and healthcare resource utilization.
Patients with self-reported gout (n = 620; 338 in US and 282 across France, Germany, and UK) were contacted based on inclusion in the 2010 US and EU National Health and Wellness Surveys (Kantar Health) and the Lightspeed Research ailment panel. Respondents were categorized into mutually-exclusive groups based on number of gout flares experienced in the past 12 months (0/don’t recall, 1–2, 3, 4–5, 6+), current presence of tophi (none, 1+, or not sure), and sUA level awareness (yes, no). HRQOL (SF-12v2), healthcare provider visits in the last 6 months, and work productivity and activity impairment (WPAI) were compared across groups.
Most patients were males, mean age of 61 years, who reported experiencing at least one acute gout flare in the past 12 months, and 12.3% (n = 76) reported presence of tophi. Among the 27.7% (n = 172) of patients who were aware of their sUA levels, higher sUA was associated with more flares and tophi. Decreased HRQOL was associated with more frequent flares and presence of tophi. In multivariable models predicting outcomes based on presence of tophi and number of flares, both flares (≥4) and tophi (≥1) were associated with HRQOL decrements on physical and mental component summary scores and health utilities (all p < 0.05), after adjustment for age, gender, and time since diagnosis. Flares were also associated with greater activity impairment.
Impairments associated with gout flares and presence of tophi, across patients in the US and EU, underscore the importance of effective management of this potentially curable condition.
Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis & Rheumatism 2011, 63:3136–3141.CrossRef
Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE: Epidemiology of gout: is the incidence rising? J Rheumatol 2002, 29:2403–2406.PubMed
Roubenoff R: Gout and hyperuricemia. Rheum Dis Clin North Am 1990, 16:539–550.PubMed
Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312–1324.PubMedCrossRef
Perez-Ruiz F: Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009,48(Suppl 2):ii9-ii14.CrossRef
Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Care & Research 2004, 51:321–325.CrossRef
Akizuki S, Matsui T: Entrapment neuropathy caused by tophaceous gout. The Journal of Hand Surgery: Journal of the British Society for Surgery of the Hand 1984, 9:331–332.
Magid SK, Gray GE, Anand A: Spinal cord compression by tophi in a patient with chronic polyarthritis: case report and literature review. Arthritis & Rheumatism 1981, 24:1431–1434.CrossRef
Sundy JS, Baraf HSB, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z: Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment. JAMA: The Journal of the American Medical Association 2011, 306:711.CrossRef
Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A: Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009, 48:582–586.CrossRef
Singh JA, Reddy SG, Kundukulam J: Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011, 23:192–202.PubMed
Khanna PP, Perez-Ruiz F, Maranian P, Khanna D: Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford) 2011, 50:740–745.CrossRef
Ware JE, Kosinski M, Turner-Bowker DM, Gandek B: How to Score Version 2 of the SF-12 Health Survey. Quality Metric, Lincoln, RI; 2002.
Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Heal Econ 2002, 21:271–292.CrossRef
Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical care 2003, 41:582.PubMed
Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M: Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. Am J Ther 2011.
Roddy E, Zhang W, Doherty M: Is gout associated with reduced quality of life? A case–control study. Rheumatology (Oxford) 2007, 46:1441–1444.CrossRef
Roubenoff R: Gout and hyperuricemia. Rheum Dis Clin N Am 1990, 16:539.
- Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Health and Quality of Life Outcomes
- Online Date
- September 2012
- Online ISSN
- BioMed Central
- Additional Links
- Quality of life
- Refractory chronic gout
- Author Affiliations
- 1. University of Michigan, Kragujevac, Michigan, USA
- 2. Western General Hospital, Edinburgh, UK
- 3. Hospital Lariboisiere, Paris, France
- 4. University Clinic, Dresden, Germany
- 5. Novartis Pharmaceuticals, Inc, East Hanover, NJ, USA
- 6. Kantar Health, New York, NY, USA
- 7. Kantar Health, Princeton, NJ, USA